Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. (NYSE: HIMS) is a health and wellness platform that regularly issues news about its digital care offerings, new specialties, and international growth. Company press releases highlight how the Hims and Hers brands use technology to connect customers with personalized care, with updates that span weight management, women’s health, labs and diagnostics, and broader platform developments.
Recent news has focused heavily on weight loss and metabolic health. Hims & Hers has launched a comprehensive Weight Loss Programme in the UK, including the official introduction of the Hers platform there, giving eligible women access to doctor-designed GLP‑1 treatment plans and holistic support for nutrition, movement, and sleep. In Canada, the company is entering the market through the acquisition of Livewell, a digital health platform focused on weight loss treatment, with plans to roll out an accessible, comprehensive weight loss program for Canadian customers.
Another key news theme is women’s health. The Hers platform has introduced a menopause and perimenopause specialty that offers eligible women access to treatment plans tailored to their health history and preferences, including prescription options such as estradiol and progesterone when deemed appropriate by licensed providers. News coverage also includes the launch of Labs, a testing experience that measures biomarkers across areas like heart health, metabolism, hormones, inflammation, and stress, pairing results with doctor-developed action plans.
Investors and followers of HIMS news will also see announcements about strategic acquisitions, such as the definitive agreement to acquire YourBio Health and its virtually painless TAP blood sampling technology, as well as corporate updates like share repurchase authorizations, financial results, leadership appointments, and facility investments. This news page aggregates these developments so readers can monitor how Hims & Hers is expanding its digital health platform, adding new capabilities, and executing its strategy across the United States, Europe, and Canada.
Hims & Hers (NYSE: HIMS) announced its official entry into Canada following the completion of its acquisition of Livewell, a Canadian digital health platform focused on weight loss.
The company said the move positions Hims & Hers to expand its digital health footprint and accelerate a comprehensive weight loss program planned for next year, timed with anticipated first availability of generic semaglutide. Hims & Hers named Austin Kouri as General Manager of Canada and Dr. Sandy Van as advisor and Chief Medical Officer in Canada. The acquisition was funded all cash from Hims & Hers’ balance sheet.
Hims & Hers (NYSE:HIMS) entered a definitive agreement to acquire YourBio Health, a Boston-based developer of capillary whole blood sampling technology, announced on December 3, 2025.
YourBio’s TAP® device and HALO™ micro-needle system use bladeless microneedles thinner than an eyelash to collect capillary blood samples pain-free in seconds; the technologies are protected by a portfolio of patents. The deal will add the technology and leadership team (Dr. Michael Mina and Paul Owen) to Hims & Hers' platform. The transaction is expected to close in early 2026, is funded entirely with cash from Hims & Hers’ balance sheet, and remains subject to customary regulatory approvals and closing conditions.
Hims & Hers (NYSE: HIMS) announced that its Board authorized a $250 million share repurchase program to buy Class A common stock over the next three years. The program follows the company’s prior $100 million repurchase, which has been fully utilized. Repurchases may occur via open market purchases, privately negotiated transactions or 10b5-1 plans, and the program can be commenced, suspended or discontinued at any time. The company said the program is supported by a strong balance sheet and projected future cash flows and is intended to provide flexibility to act when the market price may not reflect intrinsic value while maintaining focus on growth and innovation.
Hims & Hers (NYSE: HIMS) named Deb Autor as its first Chief Policy Officer on November 17, 2025 to lead global public policy, regulatory, and government affairs.
Autor brings more than three decades of experience, including roles as Deputy Commissioner for Global Regulatory Operations and Policy at the FDA, a DOJ trial attorney, Global Head of Regulatory Excellence at AstraZeneca, and CEO of Healthcare Innovation Catalysts. She will remain on the company's Board of Directors.
Hims & Hers (NYSE: HIMS) launched Labs, a subscription testing service that measures biomarkers and provides doctor-developed action plans to help customers monitor and improve health.
Two plans: Base — one annual blood draw, 50 biomarkers across 9 categories, $199/year; Advanced — two draws, 120+ biomarkers across 10 categories, $499/year. Both include clinician-reviewed results and access to personalized treatment plans if appropriate.
The company plans future expansion to at-home devices, additional biomarker panels (bone, brain), and advanced diagnostics to detect chronic and life-threatening conditions.
Hims & Hers (NYSE: HIMS) reported third quarter 2025 results with Q3 revenue of $598.98M, up 49% year‑over‑year, and Adjusted EBITDA of $78.4M, up 53% year‑over‑year. Subscribers reached 2.471 million, a 21% increase, and monthly online revenue per average subscriber rose to $80 (19% quarter over quarter). Gross margin was 74% in Q3 2025. Net income was $15.8M (Q3 2024 included a $60.8M tax benefit). Operating cash flow was $148.7M and Free Cash Flow was $79.4M in Q3.
Management narrowed full‑year 2025 guidance to $2.335B–$2.355B revenue and $307M–$317M Adjusted EBITDA. The company said it is in ongoing discussions with Novo Nordisk regarding Wegovy distribution but has no definitive agreement.
Hims & Hers (NYSE: HIMS) launched a new menopause and perimenopause specialty on October 15, 2025, expanding its women’s health services to provide tailored treatment plans starting immediately.
The platform already serves more than half a million subscribers and says it is on track to surpass $1 billion of annual revenue in 2026. Eligible customers can receive personalized plans directed by licensed providers, including prescription options such as estradiol and progesterone. The company expects an expanded range of treatment options next year. Visit forhers.com/menopause for details.
Hims & Hers (NYSE: HIMS) will report third quarter 2025 financial results after market close on Monday, November 3, 2025. A live conference call to discuss results is scheduled for 5:00 p.m. ET the same day.
U.S. dial-in is (888) 510-2630, international dial-in is (646) 960-0137, conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and archived for one year.
Hims & Hers (NYSE: HIMS) published a white paper on clinical quality, safety, and customer experience in telehealth on October 9, 2025. Key survey and operational findings show high patient confidence and low reported side effects across treatment categories.
Highlights include 94% of ~2,400 surveyed customers rating telehealth care as equal to or better than prior in-person care; 91% found intake easy; 83% reported increased confidence; and low messaging-reported side-effect rates for major categories (e.g., 0.08% for 418,000+ GLP-1 weight loss customers, 0.01%–0.08% for sexual and mental health).
The paper describes continuous clinical review by a team with >100 years combined experience and pharmacy controls aligned to FDA, USP, and state standards.
Hims & Hers Health (NYSE:HIMS) announced a major expansion into testosterone treatments through an exclusive collaboration with Marius Pharmaceuticals. The company will launch KYZATREX®, an FDA-approved oral testosterone medication, in 2026, shown to restore testosterone levels in up to 96% of men.
The platform is immediately launching personalized treatment options including compounded enclomiphene and a dual-action treatment combining enclomiphene with tadalafil. The company will also introduce injectable testosterone treatments in 2026. The initiative aims to address the estimated 20 million men in the U.S. affected by low testosterone, offering simplified access through at-home blood testing and licensed provider consultation.